SHARE

Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) ended Monday session in red amid volatile trading. The shares closed down -0.12 points or -1.22% at $9.74 with 85,536.00 shares getting traded. Post opening the session at $9.96, the shares hit an intraday low of $9.73 and an intraday high of $10.06 and the price vacillated in this range throughout the day. The company has a market cap of $349.51 million and the numbers of outstanding shares have been calculated to be 35.88 million shares.

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) announced the completion of patient enrollment of 207 patients in the randomized Phase 2 “YOSEMITE” clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of first-line metastatic pancreatic cancer.  Topline results are expected in the first half of 2017.

The YOSEMITE trial was designed to assess the efficacy and safety of demcizumab in combination with Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine (standard of care) compared to standard of care alone.  The Phase 2 dose of demcizumab was 3.5 mg/kg every two weeks for up to 70 days.  The primary endpoint of YOSEMITE is progression-free survival.  Secondary and exploratory endpoints include overall survival, response rate, pharmacokinetics, immunogenicity, safety and biomarker analyses.  Patients enrolled in the YOSEMITE Phase 2 were randomized into one of three study arms receiving 1) standard of care plus one course of demcizumab, 2) standard of care plus demcizumab followed by a second course of demcizumab after a 98-day wash-out period or 3) standard of care plus placebo.  The YOSEMITE Phase 2 trial was conducted at 49 clinical sites in the U.S., Europe and Australia.  OncoMed initiated YOSEMITE in April 2015.

Shares of Penumbra Inc (NYSE:PEN) ended Monday session in red amid volatile trading. The shares closed down -0.05 points or -0.07% at $73.90 with 82,998.00 shares getting traded. Post opening the session at $74.55, the shares hit an intraday low of $73.55 and an intraday high of $74.90 and the price vacillated in this range throughout the day. The company has a market cap of $2.29 billion and the numbers of outstanding shares have been calculated to be 31.05 million shares.

Penumbra Inc (PEN) announced that it will host a conference call to discuss financial results for the third quarter ended September 30, 2016, after market close on Thursday, November 3, 2016 at 5:00 PM Eastern Time. A press release with third quarter 2016 financial results will be issued after market close that day.

The conference call can be accessed live over the phone by dialing (877) 201-0168 for domestic callers or (647) 788-4901 for international callers (conference id: 92689865), or the webcast can be accessed on the “Investors” section of the Company’s website at: www.penumbrainc.com. The webcast will be available on the Company’s website for two weeks following the completion of the call.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here